Does humidification reduce exacerbations for people with COPD and bronchiectasis?

Does home based humidification treatment reduce exacerbation frequency for people with COPD and bronchiectasis?

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000623695

Enrollment

110

Registered

2005-10-10

Start date

2004-10-27

Completion date

2005-07-31

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Persistent airway inflammation with mucus retention in patients with chronic airway disorders such as COPD and bronchiectasis may lead to frequent exacerbations, reduced lung function and poor quality of life. This study investigates if long-term humidification therapy with high flow fully humidified air at 37 _x0002_C through nasal cannulae can improve these clinical outcomes in this group of patients.

Interventions

Daily 2 hours humidifcation treatment over a 12 month treatment period. Humidified air, fully saturated at 37 degree Celsius is delivered at 20 L/min or 25 L/min NHF via a nasal cannula.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

COPD; FEV1<70% and FEV1/FVC ratio <70%, and, > 2 exacerbation over the last 12 months, and > 5mL daily sputum production. Bronchiectasis; diagnosis of bronchiectasis confirmed by CT, and, > 2 exacerbation over the last 12 months. All subjects were recruited when stable with no sign of an exacerbation for at least 4 weeks.

Exclusion criteria

Patients with significant comorbidity, bronchiectasis associated with cystic fibrosis or hypo-gammaglobulinemia were excluded.

Outcome results